Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A study analysing overall survival in BRAFV600 mutated metastatic NSCLC and Comparing Single Arm Dabrafenib+Trametinib Clinical Trial Outcomes with Real-World Standards of Care

Next Previous
X
Search
Trial Profile

A study analysing overall survival in BRAFV600 mutated metastatic NSCLC and Comparing Single Arm Dabrafenib+Trametinib Clinical Trial Outcomes with Real-World Standards of Care

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Nov 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carboplatin (Primary) ; Pembrolizumab (Primary) ; Pemetrexed (Primary) ; Antineoplastics; Dabrafenib/trametinib; Immunotherapies
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 18 Nov 2020 New trial record
    • 16 Nov 2020 Results comparing overall survival (OS) of dabrafenib/trametinib within the 3-year trial follow up ( NCT01336634) with a similar cohort of real world patients receiving first line pembrolizumab+carboplatin+pemetrexed, or second-line PD(L)1 monotherapy,presented at the 23rd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top